Corline Biomedical AB Asset Resilience Ratio
Corline Biomedical AB asset resilience ratio. Corline Biomedical AB (CLBIO) has an Asset Resilience Ratio of 20.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CLBIO defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Corline Biomedical AB (2016–2025)
Asset resilience ratio of Corline Biomedical AB from 2016 to 2025. This chart shows how Corline Biomedical AB's Asset Resilience Ratio has changed over time. Read total liabilities of Corline Biomedical AB for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Corline Biomedical AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Corline Biomedical AB.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr20.56 Million | 20.85% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr20.56 Million | 20.85% |
Asset Resilience Insights
- Good Liquidity Position: Corline Biomedical AB maintains a healthy 20.85% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Corline Biomedical AB Industry Peers by Asset Resilience Ratio
Compare Corline Biomedical AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Corline Biomedical AB Asset Resilience Ratio by Year (2016–2025)
Corline Biomedical AB asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Corline Biomedical AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.85% | Skr20.56 Million ≈ $2.21 Million |
Skr98.58 Million ≈ $10.61 Million |
+2.21pp |
| 2024-12-31 | 18.64% | Skr17.67 Million ≈ $1.90 Million |
Skr94.76 Million ≈ $10.20 Million |
+1.65pp |
| 2023-12-31 | 16.99% | Skr17.01 Million ≈ $1.83 Million |
Skr100.11 Million ≈ $10.77 Million |
-8.76pp |
| 2022-12-31 | 25.75% | Skr26.21 Million ≈ $2.82 Million |
Skr101.78 Million ≈ $10.95 Million |
-15.20pp |
| 2021-12-31 | 40.95% | Skr41.63 Million ≈ $4.48 Million |
Skr101.66 Million ≈ $10.94 Million |
+26.09pp |
| 2020-12-31 | 14.86% | Skr8.66 Million ≈ $932.28K |
Skr58.28 Million ≈ $6.27 Million |
-20.99pp |
| 2019-12-31 | 35.85% | Skr22.86 Million ≈ $2.46 Million |
Skr63.75 Million ≈ $6.86 Million |
-8.09pp |
| 2018-12-31 | 43.94% | Skr27.64 Million ≈ $2.97 Million |
Skr62.91 Million ≈ $6.77 Million |
+11.16pp |
| 2017-12-31 | 32.78% | Skr16.86 Million ≈ $1.81 Million |
Skr51.43 Million ≈ $5.53 Million |
+4.03pp |
| 2016-12-31 | 28.74% | Skr11.86 Million ≈ $1.28 Million |
Skr41.27 Million ≈ $4.44 Million |
-- |
About Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent ha… Read more